Sign In
Buy R
$260.38
+2.32 (+0.90%)
At Close: Jun 03, 2026
Ryder CEO John Diez to Address Wells Fargo 16th Industrials & Materials Conference
06:55am, Wednesday, 03'rd Jun 2026
MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials & Materials Conference. Who: Ryder System, Inc. CEO John Diez What:
Should Value Investors Buy Ryder System (R) Stock?
10:42am, Monday, 01'st Jun 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
08:00am, Monday, 01'st Jun 2026
FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medica
Core Critical Approved for Listing on OTCQB(R) Venture Market
07:30pm, Friday, 29'th May 2026
VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Core Critical Metals Corp. ("CCMC" or the "Company") (TSXV:CCMC)(OTCQB:CCMCF) (WKN: A41G8G), a North American mineral acquisition and exploration compa
Delivra Health and Its Brands Dream Water(R) and LivRelief(TM) Report Results for Third Quarter of Fiscal 2026
05:45pm, Friday, 29'th May 2026
Third quarter sales reflect the impact of the continued changes in the global geopolitical landscape that has temporarily impacted outbound shipments from the USA to the Middle East distribution partn
Theralase(R) Releases Q1 2026 Financial Statements
05:03pm, Friday, 29'th May 2026
Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase
Here's Why Investors Should Bet on Ryder System Stock Right Now
11:56am, Thursday, 28'th May 2026
R pairs veteran-focused hiring with rising shareholder returns as earnings estimates climb and shares outperform.
New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer
02:50am, Thursday, 28'th May 2026
UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published
Totec Resources Approved for Listing on OTCQB(R) Venture Market
04:01pm, Wednesday, 27'th May 2026
VANCOUVER, BC / ACCESS Newswire / May 27, 2026 / Totec Resources Ltd. ("Totec" or the "Company") (TSXV:TOTC)(OTCQB:TTCRF)(FSE:U0Z0), a leading resource company focused on critical metals and supportin
HigherVisibility Introduces Targeted Growth System(R) for Brands Competing in AI Search
08:50am, Wednesday, 27'th May 2026
The framework centers on site speed, server response, and technical reliability as AI retrieval becomes a filter for citation and discovery. Memphis, Tennessee--(Newsfile Corp. - May 27, 2026) - Leadi
Ryder Earns VETS Indexes 3 Star Employer Award for 2026
06:55am, Wednesday, 27'th May 2026
MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) has been recognized as a 3 Star Employer in the 2026 VETS Indexes Employer Awards, underscoring the company's long‑standing commitment to recruit
Fujitsu's groundbreaking computing technology for accelerating scientific computing wins the Prime Minister's Prize in Japan
04:00am, Tuesday, 26'th May 2026
Adopted in Fujitsu's next-generation processor, FUJITSU-MONAKAKAWASAKI, Japan, May 26, 2026 - (JCN Newswire) - Fujitsu today announced that its invention for im
KottonSpa(TM) Debuts World's First Collection of SUPIMA(R) Muslin Baby Essentials.
04:32am, Monday, 25'th May 2026
New York, New York--(Newsfile Corp. - May 25, 2026) - KottonSpa™, a Texas-founded newborn brand that launched in March, introduced a collection of newborn essentials crafted entirely from 100% Ameri
BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO
05:30pm, Thursday, 21'st May 2026
BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by
Theralase(R) Closes C$4.8 Million Offering
11:06am, Wednesday, 20'th May 2026
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to th
